Home › Companies › Amicus Therapeutics, Inc. › 2025-2026

Amicus Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Amicus Therapeutics, Inc.’s Form 8-K, filed 2026-03-03 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Reported items
295Asset managers
934Fund votes
2026-03-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Amicus Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Amicus Therapeutics, Inc.

These tallies are Amicus Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-03-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Amicus Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-03-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the " Merger Agreement "), dated December 19, 2025, by and among the Company, Parent, and Lynx Merger Sub 1, Inc., a Delaware corporation and who	234,593,492	119,194	72,557	--	0	Passed
Proposal 2: The Compensation Proposal To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Merger	209,150,012	24,282,220	1,353,011	--	0	Passed

Source: Amicus Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-03-03 — read the filing on EDGAR.

How asset managers voted at the Amicus Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 295 asset managers that disclosed a Amicus Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Amicus Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to Amicus' named executive officers that is based on or otherwise relates to the Merger.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 9 wordings of this item as funds reported it.

90% Passed · of votes cast

FOR 90%10%

FOR: 209,150,012AGAINST: 24,282,220

Amicus Therapeutics, Inc.’s own tally for this item (“Proposal 2: The Compensation Proposal To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become payable to the Company's named executive officers that is based on or oth”): 209,150,012 for, 24,282,220 against — passed, per its Form 8-K filed 2026-03-03 (Item 5.07).

The 288 asset managers below cast 88% of the shares they voted on this item FOR (197,028,113 for, 26,648,348 against).

FOR 88%12%

FOR: 197,028,113 (88.1%)AGAINST: 26,648,348 (11.9%)ABSTAIN: 85,209 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the payment of certain compensation that may be paid or become p” at Amicus Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	31,637,244	0	For
Vanguard	29,465,340	25	For
Fidelity	8,191,147	12,427,000	Against
State Street	14,407,060	19,084	For
OAK RIDGE INVESTMENTS LLC	9,335,173	0	For
Pentwater Capital Management LP	9,335,173	0	For
GEODE CAPITAL MANAGEMENT, LLC	7,365,996	0	For
GLAZER CAPITAL, LLC	5,355,943	0	For
Charles Schwab	5,145,017	0	For
Nuveen	0	4,479,261	Against
TIAA	0	4,370,668	Against
AQR	4,031,434	0	For
Goldman Sachs	3,400,248	579,244	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	3,833,710	0	For
Citadel	3,409,464	0	For
Delaware/Macquarie	3,407,986	0	For
Palo Alto Investors LP	2,594,705	0	For
Northern Trust	2,574,655	0	For
TIG Advisors, LLC	2,533,230	0	For
AllianceBernstein	0	2,412,311	Against
RICE HALL JAMES & ASSOCIATES, LLC	2,272,031	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,000,000	0	For
BALYASNY ASSET MANAGEMENT L.P.	1,850,772	0	For
NEXPOINT FUNDS I	1,835,830	0	For
ALPINE ASSOCIATES MANAGEMENT INC.	1,572,176	0	For

Showing the 25 largest of 288 asset managers. See all 288 in the interactive database.

2. To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated December 19, 2025, by and among Amicus Therapeutics, Inc., a Delaware corporation ("Amicus"), BioMarin Pharmaceutical Inc., a Delaware corporation ("BioMarin"), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin ("Merger Sub"), pursuant to which

EXTRAORDINARY TRANSACTIONSCompany result: Passed

Combines 3 wordings of this item as funds reported it.

99.9% Passed · of votes cast

FOR 99.9%

FOR: 234,593,492AGAINST: 119,194

Amicus Therapeutics, Inc.’s own tally for this item (“Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the " Merger Agreement "), dated December 19, 2025, by and among the Company, Parent, and Lynx Merger Sub”): 234,593,492 for, 119,194 against — passed, per its Form 8-K filed 2026-03-03 (Item 5.07).

The 72 asset managers below cast 100% of the shares they voted on this item FOR (83,589,026 for, 0 against).

FOR 100%

FOR: 83,589,026 (100.0%)

Largest asset managers voting on “To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), da” at Amicus Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	26,929,919	For
BlackRock	19,226,223	For
State Street	8,842,380	For
Fidelity	7,349,428	For
TIAA	4,370,668	For
Delaware/Macquarie	3,407,986	For
Charles Schwab	2,571,839	For
NEXPOINT FUNDS I	1,835,830	For
Invesco	1,094,386	For
Equitable	684,998	For
PRIMECAP Odyssey Funds	589,400	For
ARBITRAGE FUNDS	578,897	For
Investment Managers Series Trust II	576,987	For
QUANTITATIVE MASTER SERIES LLC	489,676	For
Principal Exchange-Traded Funds	405,743	For
AMERICAN BEACON FUNDS	341,461	For
ProShares	278,921	For
ALPS ETF Trust	271,899	For
Direxion Shares ETF Trust	261,258	For
New York Life	260,800	For
Lincoln Financial	242,124	For
First Trust	215,521	For
Northern Trust	186,173	For
CLEARWATER INVESTMENT TRUST	177,676	For
AIG/SunAmerica	152,847	For

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

3. To approve the adjournment of the special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the adoption of the Merger Agreement at the time of the special meeting.

CORPORATE GOVERNANCE

89% fund support · no official result

FOR 89%11%

The 71 asset managers below cast 89% of the shares they voted on this item FOR (74,335,795 for, 9,228,379 against).

FOR: 74,335,795 (88.9%)AGAINST: 9,228,379 (11.0%)ABSTAIN: 24,503 (0.0%)

Largest asset managers voting on “To approve the adjournment of the special meeting, if necessary or appropriate, to solicit additional proxies ” at Amicus Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	26,929,919	0	For
BlackRock	19,226,223	0	For
State Street	22,631	8,819,749	Against
Fidelity	7,349,428	0	For
TIAA	4,370,668	0	For
Delaware/Macquarie	3,407,986	0	For
Charles Schwab	2,571,839	0	For
NEXPOINT FUNDS I	1,835,830	0	For
Invesco	1,094,386	0	For
Equitable	684,998	0	For
PRIMECAP Odyssey Funds	589,400	0	For
ARBITRAGE FUNDS	578,897	0	For
Investment Managers Series Trust II	576,987	0	For
QUANTITATIVE MASTER SERIES LLC	489,676	0	For
Principal Exchange-Traded Funds	405,743	0	For
AMERICAN BEACON FUNDS	341,461	0	For
ProShares	278,921	0	For
ALPS ETF Trust	271,899	0	For
Direxion Shares ETF Trust	261,258	0	For
New York Life	260,800	0	For
Lincoln Financial	42,724	199,400	Against
First Trust	215,521	0	For
Northern Trust	186,173	0	For
CLEARWATER INVESTMENT TRUST	177,676	0	For
AIG/SunAmerica	152,847	0	For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

4. Advisory Vote on Golden Parachutes

SECTION 14A SAY-ON-PAY VOTES

96% fund support · no official result

FOR 96%

The 6 asset managers below cast 96% of the shares they voted on this item FOR (6,367,824 for, 295,349 against).

FOR: 6,367,824 (95.6%)AGAINST: 295,349 (4.4%)

Largest asset managers voting on “Advisory Vote on Golden Parachutes” at Amicus Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
HBK INVESTMENTS L P	6,186,958	0	For
JPMorgan	0	290,536	Against
Varenne Capital Partners	180,818	0	For
CLEARWATER INVESTMENT TRUST	0	4,213	Against
Sarasin & Partners LLP	0	600	Against
Colony Family Offices, LLC	48	0	For

5. Adjourn Meeting

EXTRAORDINARY TRANSACTIONS

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (294,749 for, 0 against).

FOR: 294,749 (100.0%)

Largest asset managers voting on “Adjourn Meeting” at Amicus Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	290,536	0	0	0	For
CLEARWATER INVESTMENT TRUST	4,213	0	0	0	For

6. Approve Merger Agreement

EXTRAORDINARY TRANSACTIONS

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (294,749 for, 0 against).

FOR: 294,749 (100.0%)

Largest asset managers voting on “Approve Merger Agreement” at Amicus Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	290,536	0	0	0	For
CLEARWATER INVESTMENT TRUST	4,213	0	0	0	For

Largest Amicus Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Amicus Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting.

Top Amicus Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	Shares voted
1	BlackRock	31,637,244
2	Vanguard	29,465,365
3	Fidelity	20,618,147
4	State Street	14,426,144
5	OAK RIDGE INVESTMENTS LLC	9,335,173
6	Pentwater Capital Management LP	9,335,173
7	GEODE CAPITAL MANAGEMENT, LLC	7,365,996
8	GLAZER CAPITAL, LLC	5,355,943
9	Charles Schwab	5,145,017
10	Nuveen	4,479,261

Shown as share counts, not percentages: no shares-outstanding figure has been matched to Amicus Therapeutics, Inc. for the 2025-2026 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Amicus Therapeutics, Inc.'s shareholder meeting held 2026-03-03, in the 2025-2026 proxy season, 295 asset managers reported how they voted in their SEC Form N-PX filings, covering 934 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the payment of certain compensation that may be… — the proposal passed with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Amicus Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-03-03.

Amicus Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).